



CASE REPORT

Tigecycline therapy for bacteremia and aortitis caused by *Salmonella enterica* serotype Choleraesuis: A case report



Hung-Jen Tang^{a,b}, Chi-Chung Chen^c, Wen-Chien Ko^{d,*}

^a Section of Infectious Diseases, Department of Internal Medicine, Chi-Mei Medical Center, Tainan, Taiwan

^b Department of Health and Nutrition, Chia Nan University of Pharmacy & Science, Tainan, Taiwan

^c Institute of Biotechnology, National Cheng Kung University, Tainan, Taiwan

^d Department of Medicine, National Cheng Kung University Hospital and Medical College, Tainan, Taiwan

Received 29 July 2011; received in revised form 11 November 2011; accepted 16 January 2012

Available online 12 April 2012

KEYWORDS

Aortitis;
Bacteremia;
Salmonella enterica
serotype
Choleraesuis;
Tigecycline

Non-typhoid *Salmonella* species represent a significant cause of aortitis. Few antimicrobial agents can be used when the patient is allergic or intolerable to cephalosporins or fluoroquinolones. Here, we report a case of bacteremia and aortitis caused by *Salmonella enterica* serotype Choleraesuis. This patient was cured by initial parenteral tigecycline and subsequent oral ciprofloxacin without surgical intervention.

Copyright © 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Non-typhoid *Salmonella* species are important human food-borne pathogens and can cause extra-intestinal infections, such as bacteremia, septic arthritis, osteomyelitis and mycotic aneurysms.¹ Ampicillin, trimethoprim-sulfamethoxazole, chloramphenicol, ceftriaxone and

ciprofloxacin have been reported to be active *in vitro* and *in vivo* against *Salmonella* species.² In developed countries, there is increasing resistance to third-generation cephalosporins and fluoroquinolones among non-typhoid *Salmonella* isolates,³ thereby making the selection of appropriate antimicrobial therapy more difficult. Most antibiotics that are active *in vitro* cannot cure *Salmonella* infections, due to poor intracellular penetration.² New antibiotics like tigecycline that possess good extracellular and intracellular antibacterial activity against *Salmonella* isolates are urgently needed.^{4–7}

Tigecycline has been reported to be active *in vitro* against *Salmonella* species and to reach significant

* Corresponding author. Department of Internal Medicine, National Cheng Kung University Hospital, No. 138, Sheng Li Road, Tainan 704, Taiwan.

E-mail address: winston3415@gmail.com (W.-C. Ko).

intracellular concentrations.^{4–6} A recent study comparing the *in vitro* and *in vivo* intracellular killing effects of tigecycline with those of ceftriaxone against clinical nontyphoid *Salmonella* isolates has been published.⁷ Tigecycline exhibited sustained intracellular killing activity and resulted in better survival rates of mice with peritonitis due to multidrug-resistant *Salmonella* isolates when compared to ceftriaxone, suggesting a potential use of tigecycline for human systemic *Salmonella* infections. However, pharmacokinetic evaluations of the parenteral administration of tigecycline demonstrated low serum levels which were regarded as insufficient to exhibit bactericidal activity against intracellular pathogens.^{8,9} Here, we present a case of *Salmonella enterica* serotype Choleraesuis (*S* Choleraesuis) bacteremia and infective aortitis which were cured by initial parenteral tigecycline and subsequent long-term oral ciprofloxacin therapy without surgical intervention.

Case report

A 65-year old, non-insulin-dependent retired farmer was hospitalized because of fever and chills for more than two weeks. He had a body weight of 60 kg and was well until 3 days prior to admission to a regional hospital. Parenteral cefazolin was ineffective and intermittent fever persisted. A general skin rash over the limbs and trunk and mild dyspnea developed under cefazolin therapy. Blood cultures grew *S* Choleraesuis resistant to ampicillin, chloramphenicol, and trimethoprim/sulfamethoxazole, but susceptible to ceftriaxone and ciprofloxacin. Abdominal pain radiating to the back and tenderness over the lower abdomen were reported by the patient. An abdominal computed tomography (CT) scan disclosed infrarenal infective aortitis, a paraaortic abscess and a suspected mycotic aneurysm (Fig. 1A). Pus obtained by CT-guided percutaneous aspiration of the paraaortic abscess grew *S* Choleraesuis with the same antibiogram as the blood isolate. Based on the suspicion of a probable *Salmonella* mycotic aneurysm, the patient was transferred to the emergency department (ED) of a medical center for further evaluation and management.

After admission, a chest film showed increased patchy density over the bilateral lower lungs. Laboratory studies

revealed leukocytosis (17,500 cells/ μ L), bandemia, a high serum level of C-reactive protein (CRP, 150 mg/L) and a high erythrocyte sedimentation rate (ESR, 120 mm/h). Ciprofloxacin was prescribed, due to a suspected allergy to cephalosporins. However, severe abdominal cramping and discomfort occurred during the first infusion of ciprofloxacin. Therefore, tigecycline was administered parenterally at a loading dose of 100 mg and subsequently 50 mg every 12 hours. Because of exacerbated back pain, a spinal magnetic resonance imaging scan was performed. The images revealed a soft-tissue mass surrounding the aorta at the levels of T10-L1, lumbar spondylosis with L4-L5 disc protrusion and moderate spinal stenosis. Conservative medical treatment was suggested by the cardiovascular surgeon.

Blood cultures collected at the ED still grew *S* Choleraesuis. The minimal inhibitory concentration (MIC) of tigecycline, as determined by the broth microdilution method, was 0.5 μ g/mL. The patient's fever abated and his clinical symptoms resolved. Blood cultures after 5 days of tigecycline therapy were negative for growth and tigecycline treatment was continued for 28 days. The CT scan after one month of tigecycline therapy showed obvious shrinkage of the paraaortic abscess (Fig. 1B). Thereafter, oral ciprofloxacin at a dose of 500 mg was given every 12 hours and was tolerated well. After long-term antimicrobial therapy for four months, an abdominal CT scan revealed minimal fatty strands at the level of the infrarenal aorta (Fig. 1C). Follow-up serum studies disclosed normalization of serum CRP and ESR values.

Discussion

A review of the literature revealed that overall mortality from aortitis caused by *Salmonella* can be as high as 60%. Of patients treated non-surgically, 96% would die while 63% of patients managed by a combined medical and surgical approach would survive.¹⁰ This highlights the essential role of surgical interventions for source control in infected aortitis. Traditionally, ceftriaxone and ciprofloxacin are the standard regimens for the treatment of *Salmonella* infections.^{3,7} There has been at least one report indicative of increasing fluoroquinolone resistance in bacteremic isolates



Figure 1. (A) A computed tomography scan with contrast enhancement revealed a mild irregular contour with wall thickening in the infrarenal abdominal aorta measuring 2.8 cm \times 3.0 cm in size with surrounding amorphous-enhanced soft-tissue mass at levels T10-L1 (arrows). These characteristics are compatible with a paraaortic abscess and infective aortitis, as well as a suspected mycotic aneurysm. After tigecycline therapy for one month (B) and oral ciprofloxacin therapy for four months (C), there were minimal fatty strands at the infra-renal portion of the abdominal aorta. No additional Paraaortic abscess was found.

of *S. Choleraesuis* in southern Taiwan.¹¹ In this case, cephalosporin allergy and gastrointestinal intolerance to ciprofloxacin prohibited their use. Imipenem reportedly cured two adults with relapsing infections due to ciprofloxacin-resistant and cefotaxime-resistant *Salmonella* isolates,^{12,13} and may represent one of the treatment alternatives for human *Salmonella* infections. However, there is a lack of *ex vivo* or animal data supporting the use of carbapenem therapy for invasive *Salmonella* infections. In such a clinical setting, tigecycline, which is a glycylcycline that is effective *in vitro* with good tissue penetration, is a potential choice for the treatment of invasive human *Salmonella* infections.^{4,7} Tigecycline uptake is rapid and yields high concentrations within polymorphic neutrophils and intracellular drug concentration is 20–30 times higher than extracellular concentration.⁶ However, the use of tigecycline to treat bacteremia is questionable for patients in whom the MICs of the causative pathogen approach known serum tigecycline concentrations.¹⁴

In a recent review, tigecycline was demonstrated to be effective, safe and well tolerated in the treatment of secondary bacteremia associated with complicated intra-abdominal infections, skin and soft-tissue infections, and community-acquired pneumonia. The reported cure rates were similar to those observed for comparative standard therapy.¹⁵ Lefort et al.¹⁶ reported the potential of tigecycline therapy in a rabbit model of enterococcal endocarditis but there is no prior clinical experience with using tigecycline for the treatment of vascular infections or bacteremia caused by *Salmonella*. This is the first case of *Salmonella* bacteremia with aortitis to be successfully managed by initial tigecycline therapy and subsequent ciprofloxacin therapy without surgical intervention. Although the potential limitations of tigecycline therapy in treating bloodstream infections must be considered, the maximum serum level following a standard dosing of tigecycline in healthy subjects was 0.82 µg/mL, which was higher than the tigecycline MIC of the etiological isolate.⁵

In conclusion, our clinical experience indicates that tigecycline may be an effective treatment for bacteremia and vascular infections caused by *S. Choleraesuis*.

Acknowledgments

The authors wish to acknowledge Prof. Yin-Ching Chuang for his critical review of this article.

References

- Vugia DJ, Samuel M, Farley MM, Marcus R, Shiferaw B, Shallow S, et al. Invasive *Salmonella* infections in the United States, FoodNet, 1996-1999: incidence, serotype distribution, and outcome. *Clin Infect Dis* 2004;38(Suppl. 3):S149–56.
- Chang HR, Vladoianu IR, Pechere JC. Effects of ampicillin, ceftriaxone, chloramphenicol, pefloxacin and trimethoprim-sulphamethoxazole on *Salmonella typhi* within human monocyte-derived macrophages. *J Antimicrob Chemother* 1990;26:689–94.
- Lee HY, Su LH, Tsai MH, Kim SW, Chang HH, Jung SI, et al. High rate of reduced susceptibility to ciprofloxacin and ceftriaxone among nontyphoid *Salmonella* clinical isolates in Asia. *Antimicrob Agents Chemother* 2009;53:2696–9.
- Liu CY, Huang YT, Liao CH, Hsueh PR. In vitro activities of tigecycline against clinical isolates of *Aeromonas*, *Vibrio*, and *Salmonella* species in Taiwan. *Antimicrob Agents Chemother* 2008;52:2677–9.
- Sun HK, Ong CT, Umer A, Harper D, Troy S, Nightingale CH, et al. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. *Antimicrob Agents Chemother* 2005;49:1629–32.
- Ong CT, Babalola CP, Nightingale CH, Nicolau DP. Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs). *J Antimicrob Chemother* 2005;56:498–501.
- Tang HJ, Ko WC, Chen CC, Chen PL, Toh HS, Weng TC, et al. Tigecycline against clinical non-typhoid *Salmonella* isolates: comparisons of *in vitro* and *in vivo* intracellular killing with Ceftriaxone. *Antimicrob Agents Chemother* 2011;55:2755–9.
- Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. *J Antimicrob Chemother* 2006;58:1221–9.
- MacGowan AP. Tigecycline pharmacokinetic/pharmacodynamic update. *J Antimicrob Chemother* 2008;62(Suppl. 1):i11–6.
- Soravia-Dunand VA, Loo VG, Salit IE. Aortitis due to *Salmonella*: report of 10 cases and comprehensive review of the literature. *Clin Infect Dis* 1999;29:862–8.
- Chen PL, Wu CJ, Chang CM, Lee HC, Lee NY, Shih HI, et al. Extraintestinal focal infections in adults with *Salmonella enterica* serotype Choleraesuis bacteremia. *J Microbiol Immunol Inf* 2007;40:240–7.
- Chang CM, Lee HC, Lee NY, Huang GC, Lee IW, Ko WC. Cefotaxime-ciprofloxacin combination therapy for nontyphoid *Salmonella* bacteremia and paravertebral abscess after failure of monotherapy. *Pharmacotherapy* 2006;26:1671–4.
- Neupane GP, Kim DM, Kim SH, Lee BK. In vitro synergism of ciprofloxacin and cefotaxime against nalidixic acid-resistant *Salmonella enterica* serotypes Paratyphi A. *Paratyphi B*. *Antimicrob Agents Chemother* 2010;54:3696–701.
- Paterson DL, Doi Y. A step closer to extreme drug resistance (XDR) in gram-negative bacilli. *Clin Infect Dis* 2007;45:1179–81.
- Gardiner D, Dukart G, Cooper A, Babinchak T. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. *Clin Infect Dis* 2010;50:229–38.
- Lefort A, Lafaurie M, Massias L, Petegnief Y, Saleh-Mghir A, Muller-Serieys C, et al. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. *Antimicrob Agents Chemother* 2003;47:216–22.